secukinumab
Showing 1 - 25 of 66
Giant Cell Arteritis, Polymyalgia Rheumatica Trial (Secukinumab)
Not yet recruiting
- Giant Cell Arteritis
- Polymyalgia Rheumatica
- Secukinumab
- (no location specified)
Nov 8, 2023
Vitiligo, Secukinumab Trial in Gent (Secukinumab)
Completed
- Vitiligo
- Secukinumab
- Secukinumab
-
Gent, Oost-Vlaanderen, BelgiumDepartment of Dermatology, Ghent University Hospital
Dec 22, 2022
Rotator Cuff Tendinopathy Trial (Secukinumab, Placebo)
Not yet recruiting
- Rotator Cuff Tendinopathy
- Secukinumab
- Placebo
- (no location specified)
Feb 24, 2023
Rotator Cuff Tendinopathy Trial (Secukinumab, Placebo)
Not yet recruiting
- Rotator Cuff Tendinopathy
- Secukinumab
- Placebo
- (no location specified)
Feb 1, 2023
Non-radiographic Axial Spondyloarthritis Trial (Secukinumab, Placebo)
Not yet recruiting
- Non-radiographic Axial Spondyloarthritis
- Secukinumab
- Placebo
- (no location specified)
Nov 16, 2022
Patients Treated With Secukinumab for Moderate to Severe Plaque
Completed
- Plaque Psoriasis
- Secukinumab
-
Bangkok, ThailandNovartis Investigative Site
Dec 6, 2022
Hidradenitis Suppurativa (HS) Trial (secukinumab)
Available
- Hidradenitis Suppurativa (HS)
- secukinumab
- (no location specified)
Oct 20, 2022
Psoriasis Trial in New York (Secukinumab, Placebo followed by Secukinumab)
Completed
- Psoriasis
- Secukinumab
- Placebo followed by Secukinumab
-
New York, New YorkThe Rockefeller Univesity
Sep 26, 2022
Plaque Psoriasis Trial in Outram Park (secukinumab, Methotrexate, Cyclosporin A)
Not yet recruiting
- Plaque Psoriasis
- secukinumab
- +3 more
-
Outram Park, SingaporeSingapore General Hospital
Nov 23, 2022
Secukinumab Effectiveness in Axial Spondyloarthritis and
Completed
- Axial Spondyloarthritis
- Psoriatic Arthritis
- secukinumab
-
Madrid, Spain
- +2 more
Dec 22, 2022
Secukinumab on Clinical and Patient Reported Outcomes in
Completed
- Psoriasis
- Secukinumab
-
East Hanover, New JerseyNovartis Pharmaceuticals
Aug 22, 2022
Tendinopathy Trial in Germany (secukinumab, Placebo)
Recruiting
- Tendinopathy
- secukinumab
- Placebo
-
Berlin, Germany
- +7 more
Jan 5, 2023
Lupus Nephritis Trial (Secukinumab)
Recruiting
- Lupus Nephritis
- Secukinumab
-
Westmead, New South Wales, Australia
- +4 more
Oct 19, 2022
Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
Completed
- Psoriasis
- Secukinumab
-
East Hanover, New JerseyNovartis Investigative Site
Jun 29, 2022
Psoriasis Trial in New York (Secukinumab)
Completed
- Psoriasis
- Secukinumab
-
New York, New YorkMount Sinai West Dermatolgy
Apr 8, 2022
Necrobiosis Lipoidica Diabeticorum Trial in Boston (Secukinumab)
Terminated
- Necrobiosis Lipoidica Diabeticorum
- Secukinumab
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Feb 4, 2022
Thyroid Eye Disease, Graves Orbitopathy Trial in Germany (Secukinumab, Placebo)
Recruiting
- Thyroid Eye Disease
- Graves Orbitopathy
- Secukinumab
- Placebo
-
Essen, Germany
- +6 more
Jul 14, 2022
Non-radiographic Axial Spondyloarthritis Trial in China (Secukinumab, Placebo)
Recruiting
- Non-radiographic Axial Spondyloarthritis
- Secukinumab
- Placebo
-
Hefei, Anhui, China
- +35 more
Oct 14, 2022
Plaque Psoriasis Trial in Worldwide (biological, radiation, drug)
Recruiting
- Plaque Psoriasis
- Secukinumab
- +3 more
-
Ciudad Autonoma de Bs As, Buenos Aires, Argentina
- +66 more
Jul 20, 2022
Patterns, Effectiveness and Safety of Secukinumab in Adult
Recruiting
- Psoriasis
- secukinumab
-
Xicheng Direct, Beijing, China
- +36 more
Aug 10, 2022
Juvenile Psoriatic Arthritis, Enthesitis-related Arthritis Trial in Worldwide (secukinumab, )
Completed
- Juvenile Psoriatic Arthritis
- Enthesitis-related Arthritis
- secukinumab
- placebo
-
Los Angeles, California
- +30 more
Aug 12, 2022
Psoriatic Arthritis, Enthesitis, Biopsy Trial in Erlangen (Secukinumab)
Active, not recruiting
- Psoriatic Arthritis
- +2 more
- Secukinumab
-
Erlangen, Bavaria, GermanyUniversity Hospital Erlangen, Department of Internal Medicine 3,
Jan 27, 2022
Discoid Lupus Erythematosus Trial in Boston (Secukinumab)
Withdrawn
- Discoid Lupus Erythematosus
- Secukinumab
-
Boston, MassachusettsCURTIS (Massachusetts General Hospital)
Aug 31, 2021
Molecular Signatures in Inflammatory Skin Disease
Recruiting
- Atopic Dermatitis
- Psoriasis
- Ustekinumab
- +9 more
-
Kiel, GermanyDepartment of Dermatology, University Hospital Schleswig Holstei
Jul 16, 2022
Psoriasis Vulgaris Trial in Brooklyn (Secukinumab)
Unknown status
- Psoriasis Vulgaris
- Secukinumab
-
Brooklyn, New YorkVA NY Harbor Healthcare System
Aug 31, 2021